NAME:

CANCER DX:

DRUG NAME(S):

☐ MONOCLONAL ANTIBODIES

IMMUNOTHERAPY TX START DATE:

NOTE: IMMUNOTHERAPY AGENTS ARE **NOT** CHEMOTHERAPY AND

SIDE EFFECTS MUST BE MANAGED DIFFERENTLY. (SEE BACK)

OTHER CANCER MEDICATIONS:

**IMMUNOTHERAPY** WALLET CARD

I-O AGENTS RCV'D: □CHECKPOINT INHIBITOR(S)

☐ CAR-T ☐ VACCINES ☐ ONCOLYTIC VIRAL THERAPY

CONTACT PHONE NO.

EMERGENCY CONTACT

ОИСОГОСЬ БВОЛІВЕВ ИО.

RELATED SIDE EFFECTS.

PATIENTS HAVE A LIFETIME RISK OF IMMUNE-MAY REQUIRE REFERRAL AND STEROIDS.

CHECKPOINT INHIBITORS VARY IN SEVERITY AND IMMUNE-RELATED SIDE EFFECTS\*, COMMON WITH

## IMMUNOTHERAPY CARD ONCOLOGY PROVIDER NAME CONFER WITH ONCOLOGY TEAM BEFORE CHANGING I-O REGIMEN OR STARTING SIDE EFFECT TREATMENT. \*MAY PRESENT AS RASH, DIARRHEA, ABDOMINAL PAIN, COUGH, FATIGUE, HEADACHES, VISION CHANGES, ETC.-RELATED SIDE EFFECTS. PATIENTS HAVE A LIFETIME RISK OF IMMUNE-MAY REQUIRE REFERRAL AND STEROIDS. CHECKPOINT INHIBITORS VARY IN SEVERITY AND IMMUNE-RELATED SIDE EFFECTS\*, COMMON WITH Cut along the dotted line. **IMMUNOTHERAPY** WALLET CARD NAME: CANCER DX:\_ I-O AGENTS RCV'D: □CHECKPOINT INHIBITOR(S) ☐ CAR-T ☐ VACCINES ☐ ONCOLYTIC VIRAL THERAPY ☐ MONOCLONAL ANTIBODIES DRUG NAME(S): IMMUNOTHERAPY TX START DATE: OTHER CANCER MEDICATIONS: NOTE: IMMUNOTHERAPY AGENTS ARE **NOT** CHEMOTHERAPY AND SIDE EFFECTS MUST BE MANAGED DIFFERENTLY. (SEE BACK) CONTACT PHONE NO. IMMUNOTHERAPY CARD EMERGENCY CONTACT ОИСОГОСЬ БВОЛІДЕВ ИО. ONCOLOGY PROVIDER NAME CONFER WITH ONCOLOGY TEAM BEFORE CHANGING 1-0 REGIMEN OR STARTING SIDE EFFECT TREATMENT. →MAY PREJENT AS RASH, DIARRHEA, ABDOMINAL PAIN, COUGH, HATIGUE, HEADACHES, VISION CHANGES, ETC.

The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient's cancer treatment. Should your patient need to be seen by his/her primary care provider or in the emergency room, as an example, the card should be provided at the time of service to alert the care team of the following:

- The patient is receiving cancer treatment with immunotherapy agents
- The common side effects of immunotherapy agents
- Management of immunotherapy side effects may require a different approach than those of chemotherapy
- Oncology providers should be alerted prior to making any change in immunotherapy treatment regimens

Provide your patients receiving immunotherapy with an ONS Immunotherapy Patient Wallet Card at the time treatment with immunotherapy begins. A new card should be given to the patient whenever a cancer treatment regimen changes. Educate your patient to keep this card with them at all times, and encourage them to provide it to any healthcare provider they may visit outside of their cancer care team.

If you need additional cards, more can be downloaded from https://www.ons.org/toolkits/immunotherapy-patientwallet-card-1. Populate patient-specific information into all of the cards provided and let the patients and caregivers know to use one of the extra cards should theirs become damaged or need replacing.

## WHY IS IT IMPORTANT TO KEEP THIS CARD WITH YOU?

The ONS Immunotherapy Patient Wallet Card was designed to help you and your oncology care team communicate with other providers involved in your healthcare. Immunotherapy is a new treatment option with new side effects, and any provider involved in your healthcare must know you are on this form of treatment.

You should provide this card to any health care provider you may need to see outside of your cancer care team. An example would be your primary care provider or emergency room staff.

While you are on immunotherapy:

- Keep your immunotherapy wallet card with you at all times
- Present the card to any healthcare provider you may need to see outside of your cancer care team
- Ask your oncology team for a new card should yours become damaged or hard to read



Copyright © 2018 by the Oncology Nursing Society. All rights reserved.